Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Global Viral Conjunctivitis Pipeline Review 2016 - Research and Markets

Research and Markets
Posted on: 19 Sep 16

Research and Markets has announced the addition of the "Viral Conjunctivitis - Pipeline Review, H2 2016" drug pipelines to their offering.

Viral Conjunctivitis Viral conjunctivitis, or pinkeye, is a common, self-limiting condition that is typically caused by adenovirus. Viral conjunctivitis is highly contagious, usually for 10-12 days from onset as long as the eyes are red. Symptoms include itchy eyes, tearing, redness, discharge and light sensitivity (with corneal involvement). Treatment includes lubricants, vasoconstrictors and antihistamines.

Viral Conjunctivitis pipeline therapeutics constitutes close to 6 molecules. Out of which approximately 6 molecules are developed by Companies. The molecules developed by Companies in Phase II and Preclinical stages are 2 and 4 respectively.

Viral Conjunctivitis - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Viral Conjunctivitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Viral Conjunctivitis and features dormant and discontinued projects.

Key Topics Covered:

  1. Introduction
  2. Viral Conjunctivitis Overview
  3. Therapeutics Development
  4. Pipeline Products for Viral Conjunctivitis - Overview
  5. Pipeline Products for Viral Conjunctivitis - Comparative Analysis
  6. Viral Conjunctivitis - Therapeutics under Development by Companies
  7. Viral Conjunctivitis - Therapeutics under Investigation by Universities/Institutes
  8. Viral Conjunctivitis Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Viral Conjunctivitis - Products under Development by Companies
  13. Viral Conjunctivitis - Products under Investigation by Universities/Institutes
  14. Viral Conjunctivitis - Companies Involved in Therapeutics Development
  • Adenovir Pharma AB
  • NanoViricides, Inc.
  • Panoptes Pharma Ges.m.b.H.
  • Shire Plc
  • Starpharma Holdings Limited

For more information about this drug pipelines report visit

Related Topics: Infectious Diseases Drugs, Optical

View source version on

Business Wire

Last updated on: 19/09/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.